Altre lingue Merrimack Pharmaceuticals, Inc.

Azioni

MACK

US5903282094

Tempo reale stimato Cboe BZX Altri mercati azionari 19:07:18 09/05/2024			Variaz. 5gg	Var. 1 gen.
15,1 ^USD	+0,50%		+0,50%	+12,64%

27/03	Merrimack riceve un pagamento miliare di 225 milioni di dollari, e fissa una riunione per il piano di scioglimento	MT
07/03	Merrimack Pharmaceuticals, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	13:32
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	13:30
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	30/04
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	27/03
Merrimack Receives $225 Million Milestone Payment from Ipsen	27/03
Merrimack Reports Full Year 2023 Financial Results	07/03
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	14/02
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	14/02
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	13/02
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	13/02
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	16/11
Merrimack Reports Third Quarter 2023 Financial Results	02/11
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	18/09/23
Insider Buy: Merrimack Pharmaceuticals	09/08/23
Merrimack Reports Second Quarter 2023 Financial Results	03/08/23
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index	23/06/23
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index	23/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Merrimack Pharmaceuticals, Inc.

Azioni

MACK

US5903282094

Altre lingue

Filtri